12671 Results (Page 313 of 507)
All Market Research Reports
Egypt Pseudomonas Aeruginosa Infection Therapeutics Market Analysis
Egypt Pseudomonas Aeruginosa Infection Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Industry income is expected to increase as a result of increased pseudomonas aeruginosa infections, an ageing population, future innovative antibiotic formulations, an increase in patients, and greater public awareness of the infection. Major global players in Pseudomonas Aeruginosa Infection Therapeutics Market are Allergan, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc, Merck & Co.
US Fabry Disease Therapeutics Market Analysis
US Fabry disease Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A lack of lysosomal hydrolase -galactosidase causes Fabry disease (FD), an X-linked inborn error of lysosomal storage disorder. A activity brought on by harmful variations in the GLA gene. The market for fabry disease drugs is growing rapidly as a result of increase in incidence and prevalence of fabry disease globally, increase in awareness about the disease globally, better diagnosis rates, improved access to treatment, development of new emerging therapies, orphan drug designations provided by regulatory bodies, increase in stratergic collaborations, rise in research and development activities and approval of promising pipeline products. Chiesi Farmaceutici SpA, Sanofi, Shire, Takeda Pharmaceutical Company Limited, Amicus Therapeutics, Inc., JCR Pharmaceuticals, Moderna are the key market players operating in global fabry disease Therapeutics Market.
UK Myasthenia Gravis Therapeutics Market Analysis
UK myasthenia gravis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The myasthenia gravis market engages in all of these activities, including regulatory approvals, the introduction of new products, the purchase of other companies, and joint ventures with them. These strategies will definitely contribute to the growth of the global industry. Major global players in this market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.
France Ankylosing Spondylitis Drugs Market Analysis
France Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.
Spain Mucopolysaccharidosis I (MPS-I) Drugs Market Analysis
Spain Mucopolysaccharidosis I (MPS-I) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in Mucopolysaccharidosis I (MPS-I) Drugs Market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Drugs, Abeona Drugs, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Drugs, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
Brazil Hunter Syndrome Therapeutics Market Analysis
Brazil Hunter Syndrome Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Rare X-linked recessive genetic disorder MPS II (Hunter Syndrome) is brought on by changes in the iduronate-2-sulfatase gene (IDS). Due to the poor understanding of the illness, creating effective treatments for uncommon diseases can be difficult and expensive, which has a negative impact on the market for syndromes. Global Key Players in the Hunter Syndrome Therapeutics Market Include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceutical Inc., Shire (now a part of Takeda), Sanofi Genzyme, Ultragenyx Pharmaceutical Inc., Sangamo Therapeutics, Inc., RegenxBio Inc., Denali Therapeutics Inc., JCR Pharmaceuticals Co., Ltd., and ArmaGen Inc.
Egypt Retinal Detachment Therapeutics Market Analysis
Egypt Retinal Detachment Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The primary factor driving the market is the increase in retinal illnesses linked to diabetes on a global scale. Another important factor promoting industrial expansion is an increase in healthcare spending. Major global players in Retinal Detachment Therapeutics Market are MERIDIAN AG, IRIDEX Corporation, Ellex Medical, ZEISS, Millennium Surgical Corp., BVM MEDICAL LTD, Lombart Instrument, Welch Allyn, Inc., Aspen Surgical., Rudolf Riester GmbH, ONL Therapeutics, Keeler Ltd., Eyenuk, Inc., Inami & CO., Ltd., Trufocus Corporation, Imagine Eyes, HEALPROS, NeuroVision Imaging, Inc., Optos., Bausch & Lomb Incorporated, Alcon Vision LLC, HOYA Corporation, and Peek Vision Ltd.,
US Fanconi Anemia (FA) Therapeutics Market Analysis
US Fanconi Anemia (FA) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Aplastic anaemia and hematologic malignancies both have Fanconi anaemia as one of their most common hereditary causes. Fanconi Anemia (FA) Therapeutics Market is driven by lack of numerous competitors, limited therapeutic options, and rising illness cases. Some of the major participants in the global Fanconi Anemia (FA) Therapeutics Market include Foresee Pharmaceuticals, Jasper Therapeutics, Rocket Pharmaceuticals, Elixirgen, Genethon, and Spotlight Therapeutics.
Spain Multiple Sclerosis Drugs Market Analysis
Spain Multiple Sclerosis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Multiple sclerosis is rising due to increase in Incidence and prevalence of multiple sclerosis (MS), Improved diagnosis and awareness, advancements in healthcare infrastructure , Advancements in Treatment Options, Expanding Pipeline of Innovative Therapies, technological advancements and increase in funding for research of multiple sclerosis. Major global players in Multiple Sclerosis Drugs Market are Abbott (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc. (U.K.), Novartis AG (Switzerland), Biora Therapeutics, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Mylan N.V. (U.S.)
Brazil Huntington's Disease Therapeutics Market Analysis
Brazil huntington's disease therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for treating Huntington's disease is expanding due to a number of causes, including an increase in the disease's prevalence and a rise in the demand for modern drug types to treat the signs and symptoms of the disease. Some of the key players in the global Huntington's Disease Therapeutics Market include Pfizer, Inc. Alnylam Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd. Neurocrine Biosciences, Inc. Ionis Pharmaceuticals,Vertex Pharmaceuticals Incorporated (U.S.), Elekta AB (Sweden), Alterity Therapeutics (Australia) and som biotech (spain).
Egypt Rett Syndrome Therapeutics Market Analysis
Egypt Rett Syndrome Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Rett syndrome will grow over time as a result of expanding female population, rising public healthcare programme spending, and rising global healthcare expenditure. Major global players in Rett Syndrome Therapeutics Market are Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)
UK Myeloproliferative Disorders (MPD) Therapeutics Market Analysis
UK Myeloproliferative Disorders (MPD) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat myeloproliferative disorders is expected to expand as a result of the rising prevalence of the different myeloproliferative disorders, the existence of promising pipeline products, regular product approvals, and rising R&D expenditures on the creation of new drugs for the MPD Treatment market. Major global players in this market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol Myers Squibb Company, GSK Plc, Bayer AG, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International Gmbh, Sanofi.
France CDKL5 deficiency disorder (CDD) market Analysis
France CDKL5 deficiency disorder Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for CDKL5 deficiency disorder is expanding as a result of increase in global prevalence of CDKL5 deficiency disorder and increase in awareness about neurological diseases. In addition, high expenditure on healthcare and genetic testing, growing demand for targeted therapies, increase in R&D spending for the discovery of novel pharmaceuticals are other reasons . This demand is fueling the development of better pharmaceuticals and other treatment methods for the accurate treatment of CDKL5 deficiency disorder. Some of the key players in the global CDKL5 deficiency disorder market include Marinus pharmaceuticals, REGENXBIO, Zogenix, PTC therapeutics and Ovid therapeutics/ Takeda
Spain Myasthenia Gravis Drugs Market Analysis
Spain Myasthenia Gravis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for myasthenia gravis is rising due to increasing prevalence and incidence of disease, improved diagnostic techniques, increased awareness and better understanding of the disease, Supportive Government Initiatives like providing financial support, improving healthcare infrastructure, promoting research in rare diseases and Technological Advancements in drugs and therapies treating myasthenia gravis. Major global players in Myasthenia Gravis Drugs Market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.
Brazil Hyperhidrosis Therapeutics Market Analysis
Brazil hyperhidrosis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The increase in disease incidence, particularly axillary hyperhidrosis in industrialised nations, is one of the causes driving the market for hyperhidrosis treatments. Additionally, it is projected that increasing healthcare service demand will considerably fuel market growth, along with an increase in new product releases and product approvals.The global hyperhidrosis treatment market?s major key players are AbbVie Inc. (Allergan PLC), Brickell Biotech Inc., Eli Lilly and Company (Dermira), 1315 Capital (miraDry Inc.), SweatBlock, Merz Pharma (Merz Aesthetics), Dermavant Sciences Inc. (Roivant Sciences), Advin Health Care, Dermadry Laboratories Inc., and Dermata Therapeutics Inc
Egypt Sanfilippo Syndrome (MPS-III) Therapeutics Market Analysis
Egypt Sanfilippo Syndrome (MPS-III) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sanfilippo Syndrome (MPS-III) Therapeutics is growing rapidly as a result of increase in research and development activities, patient support and advocacy programmes, launch of new emerging therapies, increase in healthcare spending globally. Phoenix Nest Inc, Allievex Corp, Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global Sanfilippo Syndrome (MPS-III) Therapeutics market.
US Fragile-X Syndrome Therapeutics Market Analysis
US Fragile-X Syndrome Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The most typical cause of inherited learning disabilities is fragile X syndrome (FXS), an X-linked genetic disorder. The global market is driven by the higher prevalence of males than females, the transmission of the disease from one generation to the next, and the rise in patients suffering from this and other genetic disorders. Aelis Farma Sas, Alcobra Ltd, Amo Pharma Limited, Confluence Pharmaceuticals Llc, F. Hoffmann-la Roche Ltd., Marinus Pharmaceuticals, Mi.to. Technology S.r.l., Neuren Pharmaceuticals Limited, Ovid Therapeutics Inc., Sage Therapeutics, Acadia Pharmaceuticals, Advanz Pharma Corp, Boehringer Ingelheim, GlaxoSmithKline, H. Lundbeck, Janssen, Novartis, Ots.
UK Narcolepsy Therapeutics Market Analysis
UK narcolepsy therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The increased prevalence of narcoleptic disorders worldwide, rising stress levels, an ageing population, and growing public awareness of the variety of treatments for this condition are all predicted to have a positive impact on the market. Major global players in Narcolepsy Therapeutics Market are Avadel Pharmaceuticals Inc, Harmony Biosciences (BIOPROJET), Jazz Pharmaceuticals PLC, Ligand Pharmaceuticals Incorporated, Novartis, Shionogi Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals USA Inc.
France Colorectal Cancer Drugs Market Analysis
France Colorectal Cancer drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for colorectal cancer drugs is expanding due to various reasons like increase incidence and prevalence of colorectal cancer cases, increase awareness about the disease, globally ageing population. Mortality due to colorectal cancer, rising medical tourism in developing countries and benefits offered by generic medicines are other reasons. Bristol-Myer Squibb, Merck, Sanofi, Eli Lilly, Bayer are the top key market players in Global Colorectal Cancer drugs Market.
Japan Chronic Lymphocytic Leukemia Therapeutics Market Analysis
Japan Chronic Lymphocytic Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A typical form of adult Leukemia known as chronic lymphocytic Leukemia (CLL) is characterized by an excessive production of aberrant white blood cells. In most cases, it happens when the bone marrow generates damaged cells, which interfere with the formation of antibodies and eventually render them ineffective against infections. The rise in chronic lymphocytic Leukemia cases is anticipated to fuel market expansion throughout the anticipated time frame. The market will rise as a result of the various treatment options available and the familial history of chronic lymphocytic leukemia. The high cost of treatment, however, is anticipated to limit market expansion. AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Exelixis, Inc., Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Services, Inc., AbbVie Inc., MorphoSys AG, Ono Pharmaceutical Co., Ltd., and Amgen, Inc. are a few of the leading companies profiled in the chronic lymphocytic leukemia therapeutics market report.
Brazil Hypertrophic Cardiomyopathy Therapeutics Market Analysis
Brazil hypertrophic cardiomyopathy therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. In addition to heart diseases, the market for therapies for hypertrophic cardiomyopathy is primarily driven by rises in the frequency of obesity and sedentary behaviour. Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANZ PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., and Bayer AG are a few of the businesses now dominating the global hypertrophic cardiomyopathy therapeutics market.
Egypt Scleroderma Therapeutics Market Analysis
Egypt Scleroderma Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The rapid rise in scleroderma prevalence, rising frequencies of genetic anomalies, and considerable environmental changes occurring all over the world are all predicted to accelerate market expansion.Major global players in Scleroderma Therapeutics Market are Emerald Health Pharmaceuticals, Argentis Pharmaceuticals, LLC., F. Hoffmann-La Roche Ltd, AbbVie Inc., Pfizer Inc., Corbus Pharmaceuticals Holdings, Inc., Boehringer Ingelheim International GmbH, Sanofi, Allergan, viDA Therapeutics Inc., Novartis AG, Active Biotech AB., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Kadmon Holdings, Inc., Johnson & Johnson Private Limited, Liminal BioSciences Inc and AstraZeneca.
UK Neuroendocrine Tumor Therapeutics Market Analysis
UK neuroendocrine tumor therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for neuroendocrine tumors is being driven by an increase in the number of cases of these tumors. Major global players in this market are F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Viatris Inc., Thermo Fisher Scientific Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, LUPIN, Exact Sciences Corporation, Pfizer Inc., Ipsen Pharma, Advanced Accelerator Applications (a subsidiary of Novartis AG.
France Complex Regional Pain Syndrome (CRPS) Market Analysis
France Complex regional pain syndrome (CRPS) Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Complex regional pain syndrome (CRPS) is expanding as a result of rising incidence of complex regional pain syndrome and the growing number of patients suffering from chronic pain and failing back syndrome. Growth in R&D spending by both commercial and public institutions, as well as favourable government legislation and increase in product launches are other factors increasing market growth. Ovid therapeutics, Astra Zeneca, Abbott, GSK, Viatris and Johnson & Johnson Services are the top key market players in Global Complex regional pain syndrome (CRPS) market.
Japan Chronic Myelogenous Leukemia Therapeutics Market Analysis
Japan Chronic Myelogenous Leukemia Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Chronic granulocytic leukemia, often known as chronic myelogenous leukemia (CML), is a slowly progressive blood and bone marrow condition that most frequently affects adults in or after middle age and very infrequently affects children. Because of the rising incidence of the condition, the introduction of novel medications, and the expanding use of personalized medicine, the market for CML treatments is anticipated to expand gradually in the years to come. Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, and Sanofi are a few of the businesses that are now dominating the industry.